In line with this suggestion, we have noted higher serum COMP levels in women with active RA prior to starting anti-TNF-α therapy than in the control group, which may indicate an activated destructive process and significant joint damage in RA patients. This evidence concerns the gene TNF and rheumatoid arthritis.